CHPSRERT @NEJM: An ideal vaccine platform would support development from viral sequencing to clinical trials in less than 16 weeks, demonstrate elicitation of consistent immune responses across pathogens, and be suitable for large-scale manufacturing using a pathogen-agnostic platform. #COVID19 http://twitter.com/CHPSRE/status/1244843494037786624
An ideal vaccine platform would support development from viral sequencing to clinical trials in less than 16 weeks, demonstrate elicitation of consistent immune responses across pathogens, and be suitable for large-scale manufacturing using a pathogen-agnostic platform. #COVID19
— NEJM (@NEJM) March 30, 2020
from Twitter https://twitter.com/CHPSRE
March 30, 2020 at 09:26PM
via IFTTT
Comments